Why Novavax Stock Fell Today
Portfolio Pulse from Ryan Gustafson
Novavax, Inc. (NASDAQ:NVAX) shares fell over 8% on Wednesday following a surge on Tuesday after the FDA granted Emergency Use Authorization for the company's updated protein-based COVID-19 vaccine for people 12 and older. The FDA also recently approved updated vaccines from Moderna Inc (NASDAQ:MRNA) and the vaccine jointly produced by Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX).
October 04, 2023 | 11:22 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech received FDA approval for its updated COVID-19 vaccine.
The news is positive for BioNTech, but the impact on the stock price is uncertain as the approval was expected.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Moderna received FDA approval for its updated COVID-19 vaccine.
The news is positive for Moderna, but the impact on the stock price is uncertain as the approval was expected.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Pfizer received FDA approval for its updated COVID-19 vaccine.
The news is positive for Pfizer, but the impact on the stock price is uncertain as the approval was expected.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Novavax shares fell over 8% following FDA approval for its updated COVID-19 vaccine.
The drop in Novavax's stock price could be due to investors selling the news after the FDA approval, a common phenomenon in the stock market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100